← Back to Search

P4 Phantom for Glioblastoma

N/A
Recruiting
Led By Harrison Kim, PhD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients treated with surgery, followed by chemoradiation therapy, and currently under chemotherapy
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the end of cycle 2 of chemoradiation therapy (each cycle is 28 days)
Awards & highlights

Study Summary

This trial is testing whether a new device, the P4 phantom, can improve the accuracy of measuring blood flow in brain tumors. This may lead to better prognosis for brain cancer patients.

Who is the study for?
This trial is for adults over 18 with glioblastoma who've had surgery, chemoradiation, and are on chemotherapy. They must have a new or growing lesion after radiation therapy. It's not for those on dialysis, with MRI contraindications, or pregnant/planning pregnancy.Check my eligibility
What is being tested?
The study tests a device called P4 to improve blood flow measurement in brain tumors using DCE-MRI. The aim is to reduce errors across different MRI scanners and over time by using an artificial tissue standard alongside the patient's scan.See study design
What are the potential side effects?
Since this trial involves imaging rather than medication or invasive procedures, there are no direct side effects from the intervention being tested (P4). Standard MRI-related precautions apply.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I had surgery, then chemoradiation, and am now on chemotherapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the end of cycle 2 of chemoradiation therapy (each cycle is 28 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and at the end of cycle 2 of chemoradiation therapy (each cycle is 28 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Glioblastoma
To measure the reproducibility of qDCE-MRI measurement of glioblastoma.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Glioblastoma patientsExperimental Treatment1 Intervention
glioblastoma patients with newly or enlarged enhancing lesion within 3 months after completing 6 weeks of adjuvant chemoradiation therapy

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,569 Previous Clinical Trials
2,268,879 Total Patients Enrolled
10 Trials studying Glioblastoma
255 Patients Enrolled for Glioblastoma
Harrison Kim, PhDPrincipal InvestigatorUniversity of Alabama at Birmingham
2 Previous Clinical Trials
105 Total Patients Enrolled

Media Library

Point-of-care Portable Perfusion Phantom (P4) Clinical Trial Eligibility Overview. Trial Name: NCT05140902 — N/A
Point-of-care Portable Perfusion Phantom (P4) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05140902 — N/A
Glioblastoma Research Study Groups: Glioblastoma patients
Glioblastoma Clinical Trial 2023: Point-of-care Portable Perfusion Phantom (P4) Highlights & Side Effects. Trial Name: NCT05140902 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are currently engaged in this research project?

"Yes, clinicaltrials.gov affirms that this trial is currently recruiting participants. It was initially posted on the first of January 2023 and modified most recently at the end of January 2022. The research team needs to find 12 individuals for their single site study."

Answered by AI

Are there any availabilities for participants to join this investigation?

"The official record on clinicaltrials.gov shows that this research trial is still seeking participants, having been initially posted in early January of 2023 and last updated on the 31st of January 2022."

Answered by AI
~5 spots leftby Dec 2025